Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: C-C motif ligand 5 (CCL5) is reported to play a key role in acute and chronic liver diseases. However, the association between CCL5 and chronic hepatitis B (CHB) remains to be explored. We aimed to investigate the CCL5 expression in the liver tissues of CHB patients and compared the CCL5 expression among CHB patients with different stages of liver inflammation and fibrosis.
Methods: Liver tissue specimens from 51 CHB patients who underwent liver biopsy and twelve healthy liver donors were included in the present study. CCL5 expression in the liver tissues was analyzed using immunohistochemistry. The hepatic inflammation grades and fibrotic stages of CHB patients were assessed by the Scheuer classification system.
Results: Livers of CHB patients exhibited significantly accumulated CCL5+ cells when compared to those of healthy controls (42.80 ± 4.37 vs. 7.25 ± 0.99/HPF, P < .001). CHB patients with higher hepatic inflammation grades had more CCL5+ cells in their livers than those with lower grades (P < .05). However, the numbers of CCL5+ cells were not correlated with the fibrotic stages in CHB patients (r = .073, P = .61). The number of CCL5+ cells in the liver tissues of CHB patients was positively correlated with alanine transaminase levels (r = .278, P = .041) and aspartate aminotransferase levels (r = .328, P = .009).
Conclusions: CHB patients have a significant accumulation of CCL5+ cells in the liver, and CCL5 may play a pathological role in hepatic inflammation of CHB.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975458 | PMC |
| http://dx.doi.org/10.5152/tjg.2020.19566 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prescriber Specialty Involvement in Medicare Patients With Chronic Hepatitis B.
J Viral Hepat
October 2025
Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York City, New York, USA.
Chronic hepatitis B (CHB) is a major cause of liver-related morbidity and mortality in the United States. Patients with CHB require long-term antiviral treatment and consistent follow-up, but often face numerous barriers to accessing care and medications. In this study, we used the Medicare Part D database and the Rural-Urban Continuum code to explore specialty and geographic characteristics of healthcare providers that manage Medicare patients with CHB.
View Article and Find Full Text PDFPrediction of Hepatocellular Carcinoma and Other Liver-Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction-Associated Steatotic Liver Disease.
Aliment Pharmacol Ther
September 2025
Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, the Netherlands.
Introduction: Metabolic dysfunction and metabolic dysfunction-associated steatotic liver disease (MASLD) are associated with an increased risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We aimed to study risk factors for HCC and to assess the performance of the PAGE-B score in this population.
Methods: We included CHB patients with ≥ 1 metabolic comorbidity from nine centres.
Reduced Predictive Performance of the FIB-4 Index in Chronic Hepatitis B Patients With Concurrent Metabolic Dysfunction-Associated Liver Disease.
J Viral Hepat
October 2025
Technion Israel Institute of Technology, Rappaport Faculty of Medicine, Haifa, Israel.
The coexistence of chronic hepatitis B (CHB) and metabolic dysfunction-associated liver disease (MASLD) gained recognition, but the diagnostic performance of non-invasive markers regarding it remains underexplored. This study aimed to evaluate the utility of the FIB-4 index for fibrosis prediction in CHB patients and investigate its performance in the distinct subgroup of CHB-MASLD. A prospective study from 2021 to 2022 included 109 CHB and 64 CHB-MASLD patients.
View Article and Find Full Text PDFPredictive value of hepatic, hematological, and immunological markers and their temporal dynamics in chronic hepatitis B functional cure.
Microbiol Spectr
September 2025
The School of Clinical Medicine, Fujian Medical University, Fuzhou, China.
Hepatitis B virus (HBV) infection remains a major global health burden. While interferon-alpha (IFNα) therapy demonstrates antiviral and immunomodulatory effects, reliable prognostic markers for sustained response are needed. Transaminases, hematological parameters, and cytokines may serve as potential predictors, but their dynamic changes during IFNα therapy remain poorly characterized.
View Article and Find Full Text PDFImpact of tenofovir entecavir treatment on progression of chronic hepatitis B: A nationwide cohort study.
JHEP Rep
October 2025
Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.
Background & Aims: Conflicting evidence exists on hepatocellular carcinoma (HCC) risk in patients with chronic hepatitis B (CHB) receiving tenofovir entecavir. We assessed the impacts of the two drugs on the clinical trajectory of CHB at a population level.
Methods: We conducted a retrospective nationwide cohort study using data from Taiwan's National Health Insurance Research Database, including 55,885 patients with CHB who were treatment-naïve aged 30-75 years receiving tenofovir (n = 17,137) or entecavir (n = 38,748) monotherapy for ≥3 months between November 2009 and December 2020, and followed until December 2022.